Elevance Health Inc (ELV)
Official siteHEALTHCARE • HEALTHCARE PLANS • NYSE
Market Cap: $92.84B
Last updated: Nov 17, 2026 at 4:38 PM ET
Elevance Health Inc (ELV) Statistics
Elevance Health (ELV) has a market cap of $92.84B and an enterprise value of $113.25B. Its share count is down 2.78% from a year earlier.
Total Valuation
Enterprise value is 21.98% above the market cap, as debt exceeds cash.
| Market Cap | $92.84B |
|---|---|
| Enterprise Value | $113.25B |
| Latest price (Nov 17, 2026) | $433.98 |
Key Dates
The next earnings report is expected on Jan 26, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Dec 4, 2026.
| Next Earnings Date | Jan 26, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 21, 2026 |
| Next Ex-Dividend Date | Dec 4, 2026 |
| Next Payment Date | Dec 18, 2026 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 0.5x and 2.1x. Its year-end P/E ranged from 11.2x to 18.8x from 2016 to 2025.
| P/E Ratio | 14.3x |
|---|---|
| Forward P/E | 14.8x |
| P/S Ratio | 0.5x |
| Forward P/S | 0.5x |
| P/B Ratio | 2.1x |
| P/TBV Ratio | 17.2x |
| P/FCF Ratio | 14.4x |
| P/OCF Ratio | 12.2x |
| PEG Ratio | 1.7 |
Enterprise Valuation
Counting debt and cash, the company is valued at 12.4x EBITDA and 17.5x free cash flow.
| EV / Earnings | 22.2x |
|---|---|
| EV / Sales | 0.6x |
| EV / EBITDA | 12.4x |
| EV / EBIT | 14.7x |
| EV / FCF | 17.5x |
Price Statistics
The stock is up 35.27% over 52 weeks and trades 4.13% above its 50-day average.
| Beta (1Y) | 0.27 |
|---|---|
| 52-Week Change | +35.27% |
| 1-Month Change | +0.87% |
| 3-Month Change | +9.37% |
| 6-Month Change | +8.79% |
| 5-Year Change | -3.46% |
| 10-Year Change | +244.72% |
| Total Return (1Y) | +37.41% |
| Total Return (3Y CAGR) | -0.62% |
| Total Return (5Y CAGR) | +1.77% |
| Return vs SPY (1Y) | +24.25% |
| Max Drawdown (1Y) | -26.49% |
| Max Drawdown (3Y) | -50.38% |
| Sharpe Ratio (1Y) | 0.87 |
| Correlation with SPY (1Y) | 0.11 |
| 50-Day Average | $416.78 |
| 200-Day Average | $374.81 |
| 52-Week Range | $270.87 to $450.69 |
| RSI (14 Days) | 55.2 |
| Average Volume (20 Days) | 1.41M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.47x current liabilities, and total debt is 0.69x shareholder equity.
| Current Ratio | 1.47x |
|---|---|
| Quick Ratio | 1.47x |
| Debt / Equity | 0.69x |
| Debt / EBITDA | 3.35x |
| Debt / FCF | 4.72x |
| Interest Coverage | 5.33x |
Returns and Efficiency
Return on invested capital is 8.33% over the last 12 months, against a 5-year average of 10.26%.
| Return on Equity (ROE) | 11.42% |
|---|---|
| Return on Assets (ROA) | 3.99% |
| Return on Invested Capital (ROIC) | 8.33% |
| Return on Capital Employed (ROCE) | 9.48% |
| ROE (5Y Average) | 15.18% |
| ROA (5Y Average) | 5.46% |
| ROIC (5Y Average) | 10.26% |
| Asset Turnover | 1.61x |
| Receivables Turnover | 15.36x |
Taxes
Income tax took 18.35% of pretax income over the last 12 months.
| Income Tax (TTM) | $1.15B |
|---|---|
| Effective Tax Rate | 18.35% |
Scores
ELV has an Altman Z-Score of 3.07, in the safe zone above 2.99, and a Piotroski F-Score of 6 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 3.07 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 6 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $201.83B over the last 12 months is up 3.60% from the 12 months before.
| Revenue | $201.83B |
|---|---|
| Revenue Growth (YoY) | +3.60% |
| Gross Profit | $31.23B |
| Operating Income | $7.70B |
| Pretax Income | $6.25B |
| Net Income | $5.10B |
| EBITDA | $9.18B |
| EBIT | $7.70B |
| Reported EPS (TTM) | $30.35 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 34.96% of the $127.80B in total assets.
| Cash and Equivalents | $10.35B |
|---|---|
| Total Debt | $30.76B |
| Net Debt | $20.41B |
| Net Debt Per Share | $94.46 |
| Working Capital | $21.86B |
| Shareholder Equity | $44.68B |
| Book Value Per Share | $206.80 |
| Tangible Book Value | $5.46B |
| Tangible Book Per Share | $25.28 |
| Total Assets | $127.80B |
| Total Liabilities | $83.01B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.08B of capital spending, operating cash flow left $6.51B of free cash flow.
| Operating Cash Flow | $7.60B |
|---|---|
| Capital Expenditures | $1.08B |
| Free Cash Flow | $6.51B |
| FCF Per Share | $30.04 |
| Depreciation and Amortization | $1.49B |
| Dividends Paid | $1.50B |
| Share Repurchases | $2.16B |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 3.81%, against a 5-year average of 5.19%.
| Gross Margin | 15.47% |
|---|---|
| Operating Margin | 3.81% |
| Pretax Margin | 3.10% |
| Net Margin | 2.53% |
| EBITDA Margin | 4.55% |
| EBIT Margin | 3.81% |
| FCF Margin | 3.23% |
| Gross Margin (5Y Average) | 14.59% |
| Operating Margin (5Y Average) | 5.19% |
| Net Margin (5Y Average) | 3.58% |
Growth
Revenue grew 8.34% a year over 3 years, and EPS 1.27% a year.
| Revenue Growth (3Y CAGR) | +8.34% |
|---|---|
| Revenue Growth (5Y CAGR) | +10.32% |
| EPS Growth (3Y CAGR) | +1.27% |
| EPS Growth (5Y CAGR) | +6.12% |
| FCF Growth (3Y CAGR) | -24.06% |
| FCF Growth (5Y CAGR) | -19.97% |
| Operating Income Growth (3Y CAGR) | -1.36% |
Dividends and Yields
ELV pays out 19.54% of earnings as dividends.
| Dividend Per Share (Annual) | $6.88 |
|---|---|
| Dividend Yield | 1.59% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | +10.14% |
| Dividend Growth (5Y CAGR) | +12.47% |
| Payout Ratio | 19.54% |
| FCF Payout Ratio | 23.01% |
| Earnings Yield | 6.99% |
| FCF Yield | 6.95% |
| Buyback Yield | 2.30% |
| Shareholder Yield | 3.90% |
Stock Splits
The last split was a 2-for-1 forward split on Jun 1, 2005.
| Last Split Date | Jun 1, 2005 |
|---|---|
| Split Type | Forward split |
| Split Ratio | 2:1 |
Peer Position
Against 12 similar companies, ELV has the 9th highest P/E and the 6th highest P/S.
P/E RatioPeer median 28.4x
P/S RatioPeer median 0.3x
ROICPeer median 8.99%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +10.94%
Dividend YieldPeer median 0.00%
| P/E Ratio | 14.3x vs 28.4x median |
|---|---|
| P/S Ratio | 0.5x vs 0.3x median |
| ROIC | 8.33% vs 8.99% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +3.60% vs +10.94% median |
| Dividend Yield | 1.59% vs 0.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 1.15% and EPS growth at 0.19% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +1.15% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +0.19% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About ELV
What is ELV's market cap?
Elevance Health has a market cap of $92.84B. Its enterprise value, which adds debt and subtracts cash, is $113.25B.
What is ELV's P/E ratio?
Elevance Health has a trailing P/E ratio of 14.3x and a forward P/E of 14.8x.
How many shares of ELV are outstanding?
Elevance Health has 216.06M shares outstanding. The count is down 2.78% from a year earlier.
Does ELV pay a dividend?
Yes. Elevance Health pays $6.88 a share a year, a dividend yield of 1.59%.
How much debt does ELV have?
Elevance Health has $30.76B of total debt and $10.35B of cash and equivalents, a net debt position of $20.41B.
ELV pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts